Pricing Log in Create free account

Karyopharm Therapeutics Inc. (KPTI) vs Senti Biosciences, Inc. (SNTI)

Karyopharm Therapeutics Inc. and Senti Biosciences, Inc. are both Biotechnology companies. Karyopharm Therapeutics Inc. and Senti Biosciences, Inc. are of similar size ($8.1M and $8.0M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −70.7%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −3,789.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Karyopharm Therapeutics Inc. leads on 8 and Senti Biosciences, Inc. on 7.

Valuation

Metric KPTI SNTI Biotechnology median
P/E n/m n/m 8.50
P/S 0.08 5.24 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.34 0.32 9.21
Earnings yield (3,634.56%) (804.55%) (33.15%)
Free cash flow yield (580.28%) (553.67%) (25.50%)

Profitability

Metric KPTI SNTI Biotechnology median
Gross margin 95.89% 100.00% 65.16%
Operating margin (56.17%) (4,181.12%) 0.00%
Net margin (153.28%) (3,789.30%) 0.00%
Free cash flow margin (44.57%) (2,900.38%) 0.00%
Return on equity 78.98% (466.46%) (56.36%)
Return on assets (207.90%) (97.52%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KPTI SNTI Biotechnology median
Revenue growth (TTM) 6.81% (70.73%) 6.02%
EPS growth (last fiscal year) (98.37%) 77.31% 30.26%
Revenue growth, 5-year CAGR 6.21% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric KPTI SNTI Biotechnology median
Debt to equity (0.76) 0.00 0.00
Current ratio 0.79 0.83 4.72
Net debt to EBITDA (2.03) 0.25 0.96

Dividend

Metric KPTI SNTI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KPTI SNTI Biotechnology median
Market cap 7.95m 8.14m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack